Rxo annual debt-to-ebitda ratio
2021
2022
2023
2024
2025
Rxo Debt-to-EBITDA Ratio Growth & History (RXO)
Rxo's debt-to-ebitda ratio was 18.11 for fiscal 2025.
View full Rxo company overviewRxo annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 18.11 | −3.31 | −15.46% |
| 2024 | 2024-12-31 | 21.42 | 16.16 | +306.89% |
| 2023 | 2023-12-31 | 5.26 | 2.31 | +78.32% |
| 2022 | 2022-12-31 | 2.95 | 2.46 | +496.99% |
| 2021 | 2021-12-31 | 0.49 | — | — |
Rxo quarterly debt-to-ebitda ratio
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 24.27 | 8.10 | +50.10% |
| Q1 2026 | 2026-03-31 | 21.18 | −2.44 | −10.33% |
| Q4 2025 | 2025-12-31 | 18.11 | −3.31 | −15.46% |
| Q3 2025 | 2025-09-30 | 11.37 | −2.42 | −17.54% |
| Q2 2025 | 2025-06-30 | 16.17 | 7.83 | +94.00% |
| Q1 2025 | 2025-03-31 | 23.62 | 17.06 | +259.89% |
| Q4 2024 | 2024-12-31 | 21.42 | 16.16 | +306.89% |
| Q3 2024 | 2024-09-30 | 13.78 | 7.30 | +112.57% |
| Q2 2024 | 2024-06-30 | 8.33 | 2.84 | +51.64% |
| Q1 2024 | 2024-03-31 | 6.56 | 2.75 | +72.15% |
| Q4 2023 | 2023-12-31 | 5.26 | 2.31 | +78.32% |
| Q3 2023 | 2023-09-30 | 6.48 | — | — |
| Q2 2023 | 2023-06-30 | 5.50 | — | — |
| Q1 2023 | 2023-03-31 | 3.81 | — | — |
| Q4 2022 | 2022-12-31 | 2.95 | — | — |
Rxo debt-to-ebitda ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, Rxo's debt-to-ebitda ratio increased from 0.49 to 18.11, a change of 17.61. The latest reported quarter, Q2 2026, shows 24.27.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rxo source filings ↗